WellRX Acquires Bioreach
November 27, 2024
WellRX, the parent company of ReviveRX and Ways2Well, has acquired Bioreach, a bloodwork and genetics laboratory, to bring advanced diagnostic capabilities in-house. The acquisition is intended to speed testing turnaround, enable deeper diagnostic integration across WellRX’s telehealth, pharmacy and preventative-care offerings, and support scaled delivery of advanced tests to partner clinics and patients nationwide.
- Buyers
- WellRX
- Targets
- Bioreach
- Industry
- Healthcare Services
- Location
- Utah, United States
- Transaction Type
- Buyout
Explore More
Related Acquisitions
-
Discovery Life Sciences Acquires ReachBio Research Labs
April 11, 2023
Biotechnology
Discovery Life Sciences has acquired Seattle-based ReachBio Research Labs to expand its cell biology, toxicology and drug screening capabilities. The acquisition strengthens Discovery's preclinical development and multi-omics service offering, enabling customers to access a broader set of predictive cell-based assays for hematologic diseases, immunology, oncology and cell & gene therapy programs.
-
PhaseWell Research Acquires Bio Behavioral Health
January 21, 2026
Healthcare Services
PhaseWell Research, a national clinical research site company, announced that Bio Behavioral Health has joined its network to expand access to neuropsychiatric and CNS clinical trials. The deal strengthens PhaseWell's community-based research capabilities and broadens patient access to complex clinical studies across its growing national footprint.
-
Banyan Software Acquires HealthRx Corporation
June 15, 2021
Software
Banyan Software, a permanent-capital enterprise software acquirer, has purchased HealthRx Corporation, a Fairfax, Virginia–based provider of research workflow, lab safety and occupational health management software (the Nexus platform). The acquisition brings HealthRx's specialized compliance and medical surveillance capabilities into Banyan's portfolio to support continued investment and product growth in the biomedical research and government health markets.
-
Biogen Acquires Reata Pharmaceuticals
July 28, 2023
Biotechnology
Biogen Inc. agreed to acquire Reata Pharmaceuticals, Inc. for $172.50 per share in cash, representing an enterprise value of approximately $7.3 billion. The acquisition adds Reata's FDA-approved SKYCLARYS (omaveloxolone) for Friedreich's ataxia to Biogen's rare disease portfolio and is expected to be significantly accretive to Biogen's Non-GAAP diluted EPS beginning in 2025; the transaction was anticipated to close in Q4 2023.
-
LetsGetChecked Acquires BioIQ
November 16, 2021
Healthcare Services
LetsGetChecked has acquired BioIQ, an analytics-driven population health and diagnostics company, with BioIQ operating as a wholly owned subsidiary. The deal expands LetsGetChecked’s at-home diagnostics, telehealth and pharmacy capabilities and broadens its reach into health plan, employer and public-sector markets.
-
Revelation Pharma Acquires Acacia Apothecary & Wellness
October 9, 2025
Healthcare Services
Revelation Pharma, a national network of 503A and 503B compounding pharmacies, has acquired Acacia Apothecary & Wellness, a Tucson-based compounding pharmacy. The deal expands Revelation's footprint and expertise in hormone therapy, women's health, and personalized medicine; Acacia founder Justin Brock, PharmD, will join Revelation as an Operational Consultant.
Track M&A activity that matters to you
Get real-time deal alerts, build buyer lists with AI, and access our full acquisition database. Start your free trial today.